My watch list
my.bionity.com  
Login  

12 Current news about the topic gleevec

rss

You can refine your search further. Select from the filter options on the left to narrow down your results.

Novartis settles patent litigation on Gleevec with Sun Pharma subsidiary

16-May-2014

Novartis Pharmaceuticals Corporation has settled its litigation with the United States subsidiary of Sun Pharmaceutical Industries Ltd. relating to Novartis patents covering the use of certain polymorphic forms of Gleevec® (imatinib mesylate), which expire in 2019 (including pediatric ...

more

image description
Laboratory detective work points to potential therapy for cancer

17-Feb-2014

University of Pittsburgh Cancer Institute (UPCI) scientists have shown that old drugs might be able to do new tricks. By screening a library of FDA-approved anticancer drugs that previously wouldn't have been considered as a treatment for a rare type of cancer, UPCI scientists were surprised when ...

more

image description
Interaction between two leukemia drugs explained

07-Nov-2013

Currently no treatment option is available for five percent of patients suffering from chronic myelogenous leukemia, since they have developed resistance to conventional medications. Prof. Stephan Grzesiek’s group at the Biozentrum of the University of Basel, in collaboration with Dr. Wolfgang ...

more

New technology spots drugs' early impact on cancer

Fox Chase researchers find that tool could help discover new compounds or drug combinations, and quickly identify the most effective treatments for individual tumors

11-Apr-2013

A new preclinical technology enables researchers to quickly determine if a particular treatment is effective against gastrointestinal stromal tumors (GISTs), providing a boost to animal research and possibly patient care, according to new findings presented by Fox Chase Cancer Center. The ...

more

Johns Hopkins researchers say vaccine appears to 'mop up' leukemia cells Gleevec leaves behind

11-Jan-2010

Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec). Gleevec, one of the ...

more

Enzyme inhibitor takes an unexpected approach toward blocking cancer-promoting protein

09-Sep-2009

Scientists at Fox Chase Cancer Center have discovered a unique method of attack that may be used to inhibit signaling enzymes called kinases, which often have a role in sustaining drug-resistant cancerous cells. They have confirmed that IPA-3, a small molecular inhibitor of a kinase called PAK1, ...

more

Cell Genesys Provides Update on Clinical Program for GVAX Immunotherapy for Leukemia

Three New Clinical Trials Under Way

11-May-2007

Cell Genesys, Inc. reported that three new clinical trials for GVAX immunotherapy for leukemia are now under way in collaboration with the Johns Hopkins Sidney Kimmel Cancer Center. The new trials are based on encouraging results in an initial Phase 2 study of the product in patients with chronic ...

more

Infinity and MedImmune Announce Promising Biological Activity of Anti-Hsp90 Compound in Phase I GIST Trial

09-Nov-2006

Infinity Pharmaceuticals, Inc. and MedImmune, Inc. announced preliminary results from an open-label Phase I clinical study of IPI-504 in patients with Gleevec®-resistant metastatic gastrointestinal stromal tumors (GIST). IPI-504, Infinity's lead oncology drug candidate, is a proprietary small ...

more

Genzyme Launches Key Test To Monitor Gleevec Resistance

Two Additional Personalized Medicine Tests Also Available

13-Feb-2006

Genzyme Corporation announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec® (imatinib mesylate). Despite high response rates to Gleevec, approximately four to five percent of patients who were ...

more

CellGenesys Reports Positive Results From Phase 2 Trial of GVAX(R) Vaccine for Leukemia in Chronic Myelogenous Leukemia

VaccineReduces Molecular Evidence of Persistent Leukemia After Long-Term Gleevec(R) Therapy

14-Dec-2005

Cell Genesys, Inc.reported encouraging clinical data from a Phase 2 trial ofGVAX(R) vaccine for chronic myelogenous leukemia (CML). Nineteen CML patients with molecular evidence of persistent leukemia despite more than one year ofGleevec(R) (imatinib mesylate) therapy were treated with GVAX ...

more

Page 1 From 2
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE